Anika Reports Third Quarter 2026 Financial Results
Globe Newswire•06/11/2026•07:05 ET
0
Key Highlights
- ➤Q3 revenue $30.6 million, up 10% year over year
- ➤Commercial Channel revenue $14.0 million, up 17% year over year
- ➤New 10-year Hyvisc partnership expected to deliver $8 million in payments
- ➤2026 total revenue growth guidance raised to 6%-10% from 5%-10%
- ➤2026 adjusted EBITDA margin guidance raised to 15%-17% from 13%-17%
Expert Statements
Steve Griffin, President and Chief Executive Officer of Anika Therapeutics
“Through the first nine months of 2026, we have executed against the three priorities we established at the start of the year: accelerating revenue growth, strengthening operational execution and advancing our pipeline. We delivered double-digit year to date revenue growth across both channels, secured a long-term agreement that improves the durability and economics of an important commercial relationship, increased manufacturing capacity to support future growth, fully enrolled the Cingal bioequivalence study and expanded Integrity adoption,”
Steve Griffin, President and Chief Executive Officer of Anika Therapeutics
“Third quarter results reflect the continued execution against these priorities and represent key milestones to improve durable growth and drive sustained profitability. Taken together, this progress reinforces our confidence in our full-year 2026 outlook and our 2027 revenue expectations.”
Revenue Increased 10% Year Over Year, Led by 17% Commercial Channel Growth Including More Than 30% Growth in Integrity(TM )Revenue
Secured New 10-Year Hyvisc® Partnership with Enhanced Economics; Reintroduced Hyaff Non-Orthopedic OEM Product
Get started
Create a free account to read the full story.